Details for New Drug Application (NDA): 205422
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
NDA 205422 describes REXULTI, which is a drug marketed by Otsuka and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug. Additional details are available on the REXULTI profile page.
The generic ingredient in REXULTI is brexpiprazole. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the brexpiprazole profile page.
The generic ingredient in REXULTI is brexpiprazole. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the brexpiprazole profile page.
Summary for 205422
| Tradename: | REXULTI |
| Applicant: | Otsuka |
| Ingredient: | brexpiprazole |
| Patents: | 6 |
Suppliers and Packaging for NDA: 205422
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| REXULTI | brexpiprazole | TABLET;ORAL | 205422 | NDA | Otsuka America Pharmaceutical, Inc. | 59148-035 | 59148-035-13 | 1 BOTTLE in 1 CARTON (59148-035-13) / 30 TABLET in 1 BOTTLE |
| REXULTI | brexpiprazole | TABLET;ORAL | 205422 | NDA | Otsuka America Pharmaceutical, Inc. | 59148-036 | 59148-036-07 | 1 BLISTER PACK in 1 CARTON (59148-036-07) / 7 TABLET in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.25MG | ||||
| Approval Date: | Jul 10, 2015 | TE: | AB | RLD: | Yes | ||||
| Regulatory Exclusivity Expiration: | Dec 27, 2024 | ||||||||
| Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Oct 12, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Sign Up | Patent Expiration: | Apr 12, 2026 | Product Flag? | Substance Flag? | Y | Delist Request? | Y | |
Complete Access Available with Subscription
